Profiles

Keywords
Last Name
Institution

Melody Cobleigh

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Hematology/Oncology/Cell Therapy
AddressChicago IL 60612
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 7004071745.
    My NIH COMMONS name is MCOBLEIGH.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Nowicki C, Ray L, Engen P, Madrigrano A, Witt T, Lad T, Cobleigh M, Mutlu EA. Comparison of gut microbiome composition in colonic biopsies, endoscopically-collected and at-home-collected stool samples. Front Microbiol. 2023; 14:1148097. PMID: 37323911.
      View in: PubMed
    2. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. J Clin Oncol. 2023 Mar 20; 41(9):1638-1645. PMID: 36921335.
      View in: PubMed
    3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. J Clin Oncol. 2023 Mar 10; 41(8):1501-1510. PMID: 36881998.
      View in: PubMed
    4. Lieberenz J, Levy M, Alvarado R, Paul S, Cobleigh M, Usha L, Stempel L. Impact of the 2018 ACR Supplemental Screening Recommendations on MRI Eligibility in Breast Cancer Survivors. J Am Coll Radiol. 2023 01; 20(1):71-78. PMID: 36516954.
      View in: PubMed
    5. Ma CX, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, Valdez-Albini F, Cobleigh M, Jones JM, Lin NU, Winer EP, Marcom PK, Thomas S, Anderson J, Haas B, Bucheit L, Bryce R, Lalani AS, Carey LA, Goetz MP, Gao F, Kimmick G, Pegram MD, Ellis MJ, Bose R. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022 04 01; 28(7):1258-1267. PMID: 35046057.
      View in: PubMed
    6. Cobleigh MA, Anderson SJ. Reply to M. R. Van Bockstal et al. J Clin Oncol. 2021 10 20; 39(30):3410-3411. PMID: 34473528.
      View in: PubMed
    7. Cobleigh MA, Anderson SJ, Siziopikou KP, Arthur DW, Rabinovitch R, Julian TB, Parda DS, Seaward SA, Carter DL, Lyons JA, Dillmon MS, Magrinat GC, Kavadi VS, Zibelli AM, Tiriveedhi L, Hill ML, Melnik MK, Beriwal S, Mamounas EP, Wolmark N. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2367-2374. PMID: 33739848.
      View in: PubMed
    8. Kaufman PA, Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Brufsky AM, Rugo HS, Cobleigh M, Swain SM, Tripathy D, Morris A, Antao V, Li H, Jahanzeb M. Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Res Treat. 2021 Jul; 188(1):179-190. PMID: 33641083.
      View in: PubMed
    9. Elliott E, Speare V, Coggan J, Espenschied C, LaDuca H, Yussuf AF, Burgess K, Gray P, Cobleigh M, Rao R, Patel J, Kuzel T, Buckingham LE, Usha L. Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center. Cancer Rep (Hoboken). 2020 12; 3(6):e1287. PMID: 32881420.
      View in: PubMed
    10. DiScala M, Najor MS, Yung T, Morgan D, Abukhdeir AM, Cobleigh MA. Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. PLoS One. 2020; 15(6):e0234146. PMID: 32525891.
      View in: PubMed
    11. Cobleigh M, Yardley DA, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Hurvitz SA, O'Shaughnessy J, Mason G, Antao V, Li H, Chu L, Jahanzeb M. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113. PMID: 31772121.
      View in: PubMed
    12. Duarte Ow J, Hemu M, Yakupovich A, Bhatt P, Gaddam H, Prabhu N, Fughhi I, Cobleigh M, Tracy M, Fogg L, Okwuosa T. Influence of breast reconstruction on technical aspects of echocardiographic image acquisition compared with physician-assessed image quality. Cardiooncology. 2019; 5:17. PMID: 32154023.
      View in: PubMed
    13. Prabhu N, Patel H, Golemi L, Fogg L, Cobleigh M, Okwuosa T. Trastuzumab-induced cardiac toxicity: Is serial assessment of left ventricular ejection fraction during treatment necessary? Breast J. 2020 05; 26(5):1085-1086. PMID: 31674100.
      View in: PubMed
    14. Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 02; 25(2):e214-e222. PMID: 32043771.
      View in: PubMed
    15. Buckingham L, Mitchell R, Maienschein-Cline M, Green S, Hu VH, Cobleigh M, Rotmensch J, Burgess K, Usha L. Somatic variants of potential clinical significance in the tumors of BRCA phenocopies. Hered Cancer Clin Pract. 2019; 17:21. PMID: 31346352.
      View in: PubMed
    16. Turturro SB, Najor MS, Yung T, Portt L, Malarkey CS, Abukhdeir AM, Cobleigh MA. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway. Breast Cancer Res Treat. 2019 Sep; 177(2):325-333. PMID: 31209687.
      View in: PubMed
    17. Shammo JM, Usha L, Richardson KJ, Elliott E, Dewdney S, Venugopal P, Cobleigh M, Kuzel TM. Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. J Oncol Pract. 2019 07; 15(7):405-407. PMID: 31199709.
      View in: PubMed
    18. Chowdhary M, Sen N, Chowdhary A, Usha L, Cobleigh MA, Wang D, Patel KR, Barry PN, Rao RD. Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination. Adv Radiat Oncol. 2019 Jul-Sep; 4(3):453-457. PMID: 31360799.
      View in: PubMed
    19. Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 04 15; 25(8):2433-2441. PMID: 30593513.
      View in: PubMed
    20. Mitchell R, Buckingham L, Cobleigh M, Rotmensch J, Burgess K, Usha L. Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? PLoS One. 2018; 13(4):e0195497. PMID: 29659587.
      View in: PubMed
    21. Njoroge SW, Burgess KR, Cobleigh MA, Alnajar HH, Gattuso P, Usha L. Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient. Breast Cancer Res Treat. 2017 Nov; 166(1):315-319. PMID: 28702897.
      View in: PubMed
    22. Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5687-5695. PMID: 28679771.
      View in: PubMed
    23. Brann AM, Cobleigh MA, Okwuosa TM. Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent? JAMA Oncol. 2016 Sep 01; 2(9):1123-4. PMID: 27280310.
      View in: PubMed
    24. Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, von Minckwitz G, Buyse M, Piccart M. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol. 2016 06; 27(6):1029-1034. PMID: 26961151.
      View in: PubMed
    25. Turturro SB, Najor MS, Ruby CE, Cobleigh MA, Abukhdeir AM. Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. Breast Cancer Res Treat. 2016 Feb; 156(1):33-43. PMID: 26915040.
      View in: PubMed
    26. Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111(6):1241-8. PMID: 25117820.
      View in: PubMed
    27. Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, Samant M, Cobleigh M, Rimawi M, Conte P, Jin JY. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol. 2014 Aug; 74(2):399-410. PMID: 24939213.
      View in: PubMed
    28. Siziopikou KP, Anderson SJ, Cobleigh MA, Julian TB, Arthur DW, Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Eakle JF, Leasure NC, Atkins JN, Polikoff JA, Seay TE, McCaskill-Stevens WJ, Rabinovitch R, Costantino JP, Wolmark N. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013 Nov; 142(2):415-21. PMID: 24202240.
      View in: PubMed
    29. Rao R, Cobleigh M. HER2-directed treatment of metastatic breast cancer: unanswered questions. Oncology (Williston Park). 2013 Mar; 27(3):176, 178, 180. PMID: 23687785.
      View in: PubMed
    30. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, M?ller S, Thor A, Sledge GW, Sparano JA, Davidson NE, Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9. PMID: 23340303.
      View in: PubMed
    31. Rao RD, Cobleigh MA. Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park). 2012 Jun; 26(6):541-7, 550, 552 passim. PMID: 22870539.
      View in: PubMed
    32. Cobleigh MA. Other options in the treatment of advanced breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S11-6. PMID: 21600380.
      View in: PubMed
    33. Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011 Jan 15; 17(2):372-81. PMID: 21224365.
      View in: PubMed
    34. Siziopikou KP, Jokich P, Cobleigh M. Pathologic findings in MRI-guided needle core biopsies of the breast in patients with newly diagnosed breast cancer. Int J Breast Cancer. 2011; 2011:613285. PMID: 22332013.
      View in: PubMed
    35. Rao RD, Cobleigh MA, Gray R, Graham ML, Norton L, Martino S, Budd GT, Ingle JN, Wood WC. Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec; 28 Suppl 1:S39-47. PMID: 20878269.
      View in: PubMed
    36. Taylor ME, Haffty BG, Rabinovitch R, Arthur DW, Halberg FE, Strom EA, White JR, Cobleigh MA, Edge SB. ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast. Int J Radiat Oncol Biol Phys. 2009 Mar 15; 73(4):997-1002. PMID: 19251087.
      View in: PubMed
    37. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008 Oct 01; 26(28):4672-8. PMID: 18824714.
      View in: PubMed
    38. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009 May; 115(1):115-21. PMID: 18496750.
      View in: PubMed
    39. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6. PMID: 18347007.
      View in: PubMed
    40. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76. PMID: 18160686.
      View in: PubMed
    41. Moore S, Cobleigh MA. Targeting metastatic and advanced breast cancer. Semin Oncol Nurs. 2007 Feb; 23(1):37-45. PMID: 17303515.
      View in: PubMed
    42. Oleske DM, Galvez A, Cobleigh MA, Ganschow P, Ayala LD. Are tri-ethnic low-income women with breast cancer effective teachers of the importance of breast cancer screening to their first-degree relatives? Results from a randomized clinical trial. Breast J. 2007 Jan-Feb; 13(1):19-27. PMID: 17214789.
      View in: PubMed
    43. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2007 Feb; 16(1):104-7. PMID: 17097880.
      View in: PubMed
    44. Siziopikou KP, Ariga R, Proussaloglou KE, Gattuso P, Cobleigh M. The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J. 2006 Jul-Aug; 12(4):360-2. PMID: 16848847.
      View in: PubMed
    45. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2786-92. PMID: 16782917.
      View in: PubMed
    46. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8623-31. PMID: 16361546.
      View in: PubMed
    47. Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33. PMID: 16234499.
      View in: PubMed
    48. Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005 Aug; 6(3):240-6. PMID: 16137435.
      View in: PubMed
    49. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):792-9. PMID: 15681523.
      View in: PubMed
    50. Oleske DM, Cobleigh MA, Phillips M, Nachman KL. Determination of factors associated with hospitalization in breast cancer survivors. Oncol Nurs Forum. 2004 Nov 16; 31(6):1081-8. PMID: 15547631.
      View in: PubMed
    51. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29. PMID: 15545664.
      View in: PubMed
    52. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15; 22(6):1063-70. PMID: 15020607.
      View in: PubMed
    53. Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res. 2004 Mar 15; 10(6):1971-5. PMID: 15041714.
      View in: PubMed
    54. Cobleigh M, Somberg JC. A case of herceptin cardiotoxicity. Am J Ther. 2004 Jan-Feb; 11(1):74-6. PMID: 14704598.
      View in: PubMed
    55. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003 Oct; 30(5 Suppl 16):117-24. PMID: 14613032.
      View in: PubMed
    56. Cobleigh M, Frame D. Is trastuzumab every three weeks ready for prime time? J Clin Oncol. 2003 Nov 01; 21(21):3900-1. PMID: 14507945.
      View in: PubMed
    57. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9. PMID: 12732612.
      View in: PubMed
    58. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27. PMID: 12149306.
      View in: PubMed
    59. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26. PMID: 11821453.
      View in: PubMed
    60. Tangney CC, Young JA, Murtaugh MA, Cobleigh MA, Oleske DM. Self-reported dietary habits, overall dietary quality and symptomatology of breast cancer survivors: a cross-sectional examination. Breast Cancer Res Treat. 2002 Jan; 71(2):113-23. PMID: 11881909.
      View in: PubMed
    61. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42. PMID: 11694786.
      View in: PubMed
    62. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9. PMID: 11167088.
      View in: PubMed
    63. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:25-29. PMID: 11342197.
      View in: PubMed
    64. Cobleigh MA. Managing menopausal problems. Cancer Treat Res. 2000; 103:1-23. PMID: 10948439.
      View in: PubMed
    65. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999 Sep; 17(9):2639-48. PMID: 10561337.
      View in: PubMed
    66. Cobleigh MA, Norlock FE, Oleske DM, Starr A. Hormone replacement therapy and high S phase in breast cancer. JAMA. 1999 Apr 28; 281(16):1528-30. PMID: 10227323.
      View in: PubMed
    67. Cobleigh MA. Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors. Cancer Treat Res. 1998; 94:209-30. PMID: 9587690.
      View in: PubMed
    68. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997 Mar; 15(3):974-86. PMID: 9060536.
      View in: PubMed
    69. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996 May; 14(5):1718-29. PMID: 8622093.
      View in: PubMed
    70. Ghalie R, Williams SF, Valentino LA, Feingold J, Korenblit AD, Adler SS, Manson S, Pruett J, Cobleigh MA, Wolter J, Lincoln ST, Hartsell W, Kaizer H. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant. 1995 Nov; 1(1):40-6. PMID: 9118289.
      View in: PubMed
    71. Hartsell WF, Recine DC, Griem KL, Cobleigh MA, Witt TR, Murthy AK. Should multicentric disease be an absolute contraindication to the use of breast-conserving therapy? Int J Radiat Oncol Biol Phys. 1994 Aug 30; 30(1):49-53. PMID: 8083128.
      View in: PubMed
    72. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC, Wood WC. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA. 1994 Aug 17; 272(7):540-5. PMID: 8046809.
      View in: PubMed
    73. Ghalie R, Richman CM, Adler SS, Cobleigh MA, Korenblit AD, Manson SD, McLeod BC, Taylor SG, Valentino LA, Wolter J, et al. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol. 1994 Feb; 12(2):342-6. PMID: 8113841.
      View in: PubMed
    74. Ghalie R, Richman CM, Bender JG, McLeod BC, Lee W, Czyzewski A, Manson S, Cobleigh MA, Reed S, Pierre R, et al. Sequential transplants using mobilized peripheral blood progenitor cells. J Clin Apher. 1994; 9(3):176-82. PMID: 7535760.
      View in: PubMed
    75. Cobleigh MA. Breast cancer and fenretinide, an analogue of vitamin A. Leukemia. 1994; 8 Suppl 3:S59-63. PMID: 7808027.
      View in: PubMed
    76. Cobleigh MA, Dowlatshahi K, Deutsch TA, Mehta RG, Moon RC, Minn F, Benson AB, Rademaker AW, Ashenhurst JB, Wade JL, et al. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol. 1993 Mar; 11(3):474-7. PMID: 8445423.
      View in: PubMed
    77. Lad TE, Blough RR, Evrard M, Shevrin DP, Cobleigh MA, Johnson CM, Hange P. Phase II trial of spirogermanium in advanced non-small cell lung cancer. An Illinois Cancer Council Study. Invest New Drugs. 1989 Jul; 7(2-3):223-4. PMID: 2551841.
      View in: PubMed
    78. Shevrin DH, Lad TE, Kilton LJ, Cobleigh MA, Blough RR, Weidner LL, Vogelzang NJ. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study. Invest New Drugs. 1989 Jul; 7(2-3):251-3. PMID: 2477345.
      View in: PubMed
    79. Cobleigh MA, Kennedy JL, Wong AC, Hill JH, Lindholm KM, Tiesenga JE, Kiang R, Applebaum EL, McGuire WP. Primary culture of squamous head and neck cancer with and without 3T3 fibroblasts and effect of clinical tumor characteristics on growth in vitro. Cancer. 1987 May 15; 59(10):1732-8. PMID: 3828946.
      View in: PubMed
    80. Cobleigh MA, Hill JH, Lad TE, Shevrin DE, Applebaum EL. Phase II study of etoposide in previously untreated squamous cell carcinoma of the head and neck. Cancer Treat Rep. 1987 Mar; 71(3):321-2. PMID: 3815398.
      View in: PubMed
    81. Shevrin DH, McGuire WP, Lanzotti V, Krauss S, Blough R, Cobleigh M, Johnson C, Lad T, Kukla L. Phase II trial of aminothiadiazole in advanced non-small cell lung cancer. Cancer Treat Rep. 1986 Mar; 70(3):417-8. PMID: 3955556.
      View in: PubMed
    82. Cobleigh MA, Hill JH, Gallagher PA, Kukla LJ, Lad TE, Shevrin DH, Applebaum EL, McGuire WP. A phase II study of Adriamycin in previously untreated squamous cell carcinoma of the head and neck. Cancer. 1985 Dec 01; 56(11):2573-5. PMID: 4052934.
      View in: PubMed
    83. McGuire WP, Blough RR, Cobleigh MA, Johnson CM, Kukla LJ, Lad TE, Lanzotti VJ, Stiff PJ, Zawila P. Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study. Cancer Treat Rep. 1983 Sep; 67(9):841-2. PMID: 6883363.
      View in: PubMed
    84. Kuzur ME, Cobleigh MA, Greco FA, Einhorn LH, Oldham RK. Endodermal sinus tumor of the mediastinum. Cancer. 1982 Aug 15; 50(4):766-74. PMID: 7093910.
      View in: PubMed
    85. Cobleigh MA, Williams SD, Einhorn LH. Phase II study of vindesine in patients with metastatic breast cancer. Cancer Treat Rep. 1981 Jul-Aug; 65(7-8):659-63. PMID: 7248983.
      View in: PubMed
    Cobleigh's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (307) concept(s)
    _
    Co-Authors Expand Description
    See all (16) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department